lifestyle.spaziotribu.net

Author: NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

April 14, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

April 6, 2026
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

March 26, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

March 17, 2026
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

March 10, 2026